Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Next Previous
Trial Profile

A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Decompensated heart failure; Myocardial infarction; Stroke; Thrombosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COMMANDER-HF
  • Sponsors Bayer; Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 01 Jan 2022 Results published in the Clinical Research in Cardiology
    • 03 Aug 2021 Results of systematic review and meta-analysis fom COMMANDER HF, ATLAS ACS 2-TIMI 51 and COMPASS; evaluating efficacy and safety of rivaroxaban in patients with coronary artery disease, heart failure and sinus rhythm, published in the European Journal of Clinical Pharmacology
    • 17 May 2021 Results of Meta-Analysis from Atlas-ACS-2 TIMI-51, COMMANDER HF, COMPASS and VOYAGER PAD; assessing whether low-dose Rivaroxaban is associated with reduction in ischemic outcomes but with increased bleeding, presented at the 70th Annual Scientific Session of the American College of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top